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Abstract
Background: This study prospectively assessed the occurrence of clinical and subclinical schistosomiasis,
strongyloidiasis, filariasis, and toxocariasis, and the screening value of eosinophilia in adult short-term travelers to
helminth-endemic countries.
Methods: Visitors of a pre-travel health advice centre donated blood samples for serology and blood cell count
before and after travel. Samples were tested for eosinophilia, and for antibodies against schistosomiasis,
strongyloidiasis, filariasis, and toxocariasis. Previous infection was defined as seropositivity in pre- and post-travel
samples. Recent infection was defined as a seroconversion. Symptoms of parasitic disease were recorded in a
structured diary.
Results: Previous infection was found in 112 of 1207 subjects: schistosomiasis in 2.7%, strongyloidiasis in 2.4%,
filariasis in 3.4%, and toxocariasis in 1.8%. Recent schistosomiasis was found in 0.51% of susceptible subjects at risk,
strongyloidiasis in 0.25%, filariasis in 0.09%, and toxocariasis in 0.08%. The incidence rate per 1000 person-months
was 6.4, 3.2, 1.1, and 1.1, respectively. Recent infections were largely contracted in Asia. The positive predictive
value of eosinophilia for diagnosis was 15% for previous infection and 0% for recent infection. None of the
symptoms studied had any positive predictive value.
Conclusion: The chance of infection with schistosomiasis, strongyloidiasis, filariasis, and toxocariasis during one
short-term journey to an endemic area is low. However, previous stay leads to a cumulative risk of infection.
Testing for eosinophilia appeared to be of no value in routine screening of asymptomatic travelers for the four
helminthic infections. Findings need to be replicated in larger prospective studies.
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Background
Helminth infections are a major health problem in the
developing world. Due to increased travel to developing
countries and changes in travel behavior, they have
gained importance in the developed world, particularly
among travelers [1].
Untreated helminth infection may result in long-term
adverse outcomes. Because symptomatology can be
absent or non-specific, blood eosinophil count is com-
monly used as a screening tool [2-4]. Schistosomiasis,
strongyloidiasis, filariasis, and toxocariasis are four com-
mon helminth infections associated with eosinophilia [4].
Schistosoma trematodes can penetrate human skin
exposed to contaminated fresh water. Endemic in Africa,
Central and South America, and Asia, about 200 million
people worldwide are infected [5,6]. The major species
give rise primarily to intestinal, hepatic and urinary
pathology [7].
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intact skin after contact with contaminated soil. It is
endemic in tropical, subtropical and temperate regions,
affecting 30-100 million people. Manifestations range
from asymptomatic to chronic symptomatic disease [8,9].
Filarial morbidity is caused primarily by 4 nematode
species. Of these, Wuchereria bancrofti and Brugia
malayi are transmitted by mosquitoes and reside in the
lymphatics. W. bancrofti is endemic throughout the
developing world; B. malayi is limited to Asia. More
than 120 million people worldwide are infected [7].
Onchocerca volvulus is transmitted by blackflies and
resides in subcutaneous nodules and in the eye. It is
endemic mainly in sub-Saharan Africa, with additional
foci in Central and South America and the Middle-East.
About 17.7 million people are infected [10]. Loa loa is
transmitted by flies and causes subcutaneous swellings.
It is endemic in sub-Saharan Africa [7].
Toxocariasis is caused by ingestion of eggs of the
nematodes Toxocara canis or Toxocara cati, via contami-
nated soil. It is distributed worldwide. Manifestations
vary with regard to which tissue has been invaded [11].
Research on the prevalence and incidence of these
infections among travelers is scarce. Studies on the pre-
dictive value of eosinophilia for asymptomatic helminth
infection have shown different correlations, and its diag-
nostic relevance remains controversial [3,4]. Moreover,
most studies use retrospective study designs.
This study prospectively estimates the prevalence and
incidence of schistosomiasis, strongyloidiasis, filariasis,
and toxocariasis based on serologic testing in a cohort
of short-term travelers to endemic areas. It evaluates
risk factors, and assesses the diagnostic relevance of
eosinophilia.
Methods
Study population
A prospective study was performed among persons
attending the travel clinic of the Public Health Service
Amsterdam from October 2006 to October 2007. All per-
sons 18 years and older were eligible if planning to travel
for 1-13 weeks to one or more developing countries. As
defined by the United Nations Development Agency
(UNDA), these countries were in the Caribbean and Cen-
tral and South America; Western, Middle, Eastern and
Southern Africa; South-Eastern Asia and China, and the
South-Central Asian area of Afghanistan, Bangladesh,
Bhutan, India, Nepal, Pakistan, and Sri Lanka [12].
All participants were seen by a medical doctor or
nurse specialised in travel medicine. They received vac-
cinations, a prescription for anti-malarial chemoprophy-
laxis if required, and oral and written information about
how to avoid acquiring travel-related diseases, based on
Dutch National Guidelines on Traveller’s Health Advice.
Survey methods
Before departure and 2 to 6 weeks after return, partici-
pants donated venous blood samples for serology and
blood cell count. Before departure, a standard question-
naire was used to collect data on socio-demographics,
including purpose of travel. Participants were also asked
to keep a structured travel diary, recording symptoms
and signs of parasitic disease (fever, myalgia, skin infec-
tion, and gastro-intestinal disorder), from the day they
arrived at the destination until 2 weeks after return, to
encompass incubation periods of acute travel-related
infections. Thus ‘travel-related’ refers to the period of
travel and the two weeks thereafter.
Destinations were grouped into regions using the
UNDA classification [12]. Travel duration was recorded
as the total days spent in areas meeting the inclusion
criteria.
The study protocol was approved by the Medical
Ethics Committee of the Academic Medical Centre
Amsterdam. Participants were included only after
informed and written consent.
Laboratory methods
All blood samples were immediately stored at 6°C. The
total leukocyte count and the eosinophil count of both
pre-travel and post-travel samples were determined
within 24 hours by automated analyzer (Sysmex SE-
9 0 0 0 ,T o aM e d i c a lI n s t r u m e n t s ,K o b e ,J a p a n ) .B l o o d
samples for serologic testing were centrifuged and fro-
zen at -80°C within 24 hours, to be tested after all parti-
cipants had returned. For serodiagnosis of Schistosoma
mansoni, haematobium,a n djaponicum, an indirect
hemagglutination assay (IHA) with adult S. mansoni
worm antigens (Fumouze Laboratories, Levallois-Perret,
France) and an enzyme-linked immunosorbent assay
(ELISA) with S. mansoni soluble egg antigens were used
[13]. For S. stercoralis, an in-house ELISA based on anti-
gen of S. stercoralis was used [14]. For filariasis, a com-
mercially available ELISA on microtitration wells
sensitized with Acanthocheilonema viteae somatic anti-
gens was used (Bordier Affinity Products, Crissier, Swit-
zerland). For toxocariasis, a commercially available
ELISA on microtitration wells sensitized with T. canis
E/S larval antigens was used (Bordier Affinity Products,
Crissier, Switzerland).
Sensitivity and specificity in clinical settings were
100% and 93% for the combined IHA and ELISA for
Schistosomiasis; 93% and 95% for the ELISA for Strongy-
loides; 95% and 98% for the ELISA for filariasis; and
91% and 86% for the ELISA for Toxocariasis [13-16].
For participants whose post-travel sample tested posi-
tive, pre-travel samples were also tested. Previous infec-
tion was defined as a seropositive pre- and post-travel
sample. Recent infection was defined as a seropositive
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for a given disease, i.e. seroconversion. In a traveler
whose post-travel sample was just above the cut-off and
whose pre-travel sample was just below the cut-off, pre-
vious infection was assumed.
Data analysis
Participants were considered to be at risk for a specific
infection if they had spent one day or more in an ende-
mic area. Endemicity was based on information from
The Global Infectious Diseases and Epidemiology
Online Network [17]. Participants were considered sus-
ceptible for a given disease in case of a seronegative
pre-travel sample.
Attack rates per 100 travelers were calculated by
dividing the number of seroconversions by the total
number of participants at risk and susceptible for the
given infection. Incidences rates per 1000 person-
months were calculated by dividing the number of sero-
conversions by the total number of months in which
participants were at risk for infection. Attack rates and
incidence rates were calculated using OpenEpi, version
2.3 [18].
Eosinophilia was defined as an eosinophil count of
more than 450 per mm
3. The predictive value of eosino-
philia defined as ≥8% or ≥10% eosinophils per total leu-
kocyte count was also examined. For travelers with
recent infection, the eosinophil counts of post-travel
samples were analyzed. For travelers with previous hel-
minth infection and for seronegative travelers, the pre-
travel eosinophil counts were analyzed. The sensitivity
of eosinophilia for the serology-based presence of para-
sitic infection was calculated by dividing the number of
seropositive participants with eosinophilia by the num-
ber of all seropositive participants. Specificity was calcu-
lated by dividing the number of seronegative
participants without eosinophilia by the number of all
seronegative participants. The positive predictive value
(PPV) was calculated by dividing the number of seropo-
sitive participants with eosinophilia by the number of all
participants with eosinophilia. The negative predictive
value (NPV) was calculated by dividing the number of
seronegative participants without eosinophilia by the
number of all participants without eosinophilia.
To calculate risk factors for previous infection, SPSS
for Windows version 17.0 (SPSS Inc., Chicago) was used
to obtain prevalence rates (PRs), univariate and multi-
variate prevalence rate ratios (PRRs), and 95% confi-
dence intervals (CIs), by means of logistic regression
modeling. All variables with an overall p-value < 0.05 in
univariate analysis were included in multivariate analy-
sis. Statistical interactions between variables were
checked for all variables. If significant (p < 0.05), they
were included in multivariate analysis.
Chi-square tests were used to evaluate the predictive
value of travel-related symptoms for recent infection.
Fever was defined as a body temperature ≥38°C. A p-
value < 0.05 was considered statistically significant.
Results
Study population
The study began with 1276 subjects who intended to
travel to the developing world. Of these, 69 (5.4%) were
excluded: 33 were lost to follow-up, 23 had their travel
arrangements cancelled, 7 did not supply the post-travel
blood donation, 3 changed travel plans such that inclu-
sion criteria were not met, 2 did not complete the struc-
tured diary, and for 1 case, the post-travel sample was
lost.
Table 1 describes the remaining 1207 subjects. The
vast majority were native Dutch tourists travelling for
holiday purposes. On this trip, all visited one or more
countries endemic for S. stercoralis, filariasis, and toxo-
cariasis, and 1006 visited one or more countries ende-
mic for schistosomiasis. The characteristics of the latter
did not differ from the characteristics of all 1207 sub-
jects (data not shown).
Serology suggestive for previous and recent infection
Serology suggestive for previous infection was found 124
times in 112 of 1207 subjects: for schistosoma spp.i n3 2
(2.7%; 95%CI: 1.9-3.7%); for S. stercoralis in 29 (2.4%;
95%CI: 1.6-3.4%); for filariasis in 41 (3.4%; 95%CI: 2.5-
4.5%); and for toxocara spp. in 22 (1.8%; 95%CI: 1.2-
2.7%). Ten of 112 travelers had serology suggestive for 2
previous infections and 1 for 3 previous infections.
T h r e eo f3 2( 9 . 4 % )w i t hp r e v i o u ss c h i s t o s o m i a s i sa n d4
of 41 (9.8%) with previous filariasis did not report birth
or previous travel to a developing country.
Serology suggestive for recent infection was found in
10 cases: for schistosoma spp. in 5 of 979 susceptible
subjects at risk (0.51%), for S. stercoralis in 3 of 1178
(0.25%), for filarial spp. in 1 of 1166 (0.086%), and for
toxocara spp. in 1 of 1185 (0.084%). The incidence rate
per 1000 person-months was 6.4 for schistosomiasis, 3.2
for strongyloidiasis, 1.1 for filariasis, and 1.1 for toxocar-
iasis. Table 2 shows the attack rates and incidence rates,
overall and per region. The characteristics, travel-related
symptoms, and pre- and post-travel eosinophil counts of
recently infected subjects are shown in Table 3. None
had serology suggestive for more than one recent infec-
tion. The median interval between return from travel
and blood donation for these ten travelers was 25 days
(range 23-28).
Eosinophilia
The median pre-travel eosinophil count among all 1207
subjects was 150 per mm
3 (95%CI: 30-560), and 55
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nificantly differ from subjects without eosinophilia in
sociodemographics, travel characteristics, or travel-
related symptoms (p>0.05).
Among the 112 subjects with previous infection, the
median eosinophil count was 150 per mm
3 (95%CI: 30-
664), and 8 (7.1%) had eosinophilia. The sensitivity of
eosinophilia for serological diagnosis of previous infec-
tion was 7%, the specificity 96%, the PPV 15%, and the
NPV 91%. When eosinophilia was defined as ≥8% eosi-
nophils per total leukocyte count, the PPV was 14%.
When eosinophilia was defined as ≥10% eosinophils per
total leukocyte count, the PPV increased to 20%,
whereas the NPV remained 91%.
Among the 10 subjects with recent infection, the med-
ian eosinophil count was 130 per mm
3 (95%CI: 60-330);
none had eosinophilia. Thus, the sensitivity and PPV of
eosinophilia for the serological diagnosis of recent infec-
tion were 0%; the specificity and NPV were 95% and
99%, respectively. When eosinophilia was defined as
≥8% or ≥10% eosinophils per total leukocyte count, the
PPV remained 0%.
Risk factors and markers for previous and recent infection
Table 4 shows the PRs and PRRs with accompanying
95% confidence intervals and p-values for potential risk
factors for previous infection. The prevalence rate was
significantly higher for male travelers, for travelers with
frequent previous travel to a developing country, and for
travelers going for work/education or visiting friends
and/or relatives. There were no interactions indicating
effect-modification.
Previous infection was not related to disease symp-
toms during the current trip or eosinophilia: ORs
equaled 1.0 with p-values > 0.05 (not shown in Table).
Compared to all seronegative subjects, the 10 subjects
w i t hr e c e n ti n f e c t i o nw e r em o r eo f t e nb o r ni nan o n -
western country (30% vs. 7%; OR 5.8, 95%CI: 1.2-22.7;
p-value: 0.031), and their current travel destination was
more often Asia (83% vs. 47%; OR 5.6, 95%CI: 1.4-38.0;
p-value: 0.014). Recent infection was not related to tra-
vel duration, the interval between return from travel
and blood donation, disease symptoms nor to eosinophi-
lia (ORs equaled 1.0 with p-values > 0.05).
Discussion
In this prospective study the serology-based attack rates
and incidence rates of recent schistosomiasis, strongyloi-
diasis, filariasis, and toxocariasis in short-term travelers
to endemic areas were low. Recent infection with any of
the 4 parasites was found in only 0.8% of travelers, and
disease-specific incidences ranged between 1.1 and 6.4
per 1000 person-months of travel. However, as much as
9.3% of travelers had previous infection, indicating that
exposure from a previous stay raises risk of infection.
Indeed, previous infection was related to a history of fre-
quent travel to developing countries. Since toxocariasis
is endemic in developed and developing countries, rates
of previous toxocara infections are of limited value from
a travel-medicine perspective.
Table 1 Characteristics of a cohort of 1207 travelers to
developing countries, attending a Dutch Travel Health
Clinic for pre-travel health advice, October 2006 -
October 2007
Number of subjects 1207
Male sex 521 43%
Median age in years ° 38 (29-51)
Country of birth
Netherlands 1049 87%
Other Western country 69 6%
Non-Western country 89 7%
Current travel destination
South-east Asia 375 31%
South and West Asia 147 12%
East Asia 98 8%
South America 219 18%
Central America and Caribbean 135 11%
East Africa 140 12%
West and Middle Africa 113 9%
Southern Africa 67 6%
Primary purpose of travel
Tourism 1032 86%
Work or education 99 8%
Visiting friends and/or relatives 76 6%
Median travel duration in days ° 21 (16-28)
Median interval between return from
travel and blood donation, in days ° 25 (21-29)
Previous travel to a developing country
Never 221 18%
1 to 5 times 703 58%
6 times or more 283 23%
Previous travel destinations
Asia 670 56%
Latin America 546 45%
Africa 528 44%
° Interquartile range between brackets
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tive value for seroconversion or pre-existing seropositiv-
ity. The PPV of eosinophilia was low, being 15% for
diagnosis of previous infection and 0% for recent
infection.
Studies on travel-related helminth infection have
reported schistosomiasis in 1.3-1.6% of travelers, stron-
gyloidiasis in 0.1-1.2%, and filariasis in 0.6-1.0%
[3,19-21]. A study on travel-related toxocariasis could
not be identified. Eosinophilia was found in only 38-65%
of patients with filariasis, strongyloidiasis, and/or schis-
tomiasis, and its PPV was low [1,3,4]. All aforemen-
tioned studies used a retrospective and cross-sectional
study design based on immigrants, expatriates, or tour-
ists who sought medical attention after return. They are
influenced by referral bias, cannot compare characteris-
tics to those who have remained well, and lack valid
denominator data to determine absolute risk. Thus com-
paring their findings with ours is difficult. Nevertheless,
as the PPV is generally proportional to disease
occurrence, the PPV of eosinophilia was expected to be
even lower in our cohort of asymptomatic travelers with
a low incidence of infection. Also, eosinophilia can arise
from other medical conditions, including allergic disor-
ders. One can conclude that routine screening for eosi-
nophilia of asymptomatic travelers after return
apparently has no value.
In our study, most of the recent infections were con-
tracted in India and South-east Asia. In other studies,
most parasitic infections, in particular schistosomiasis
and filariasis, were contracted in sub-Saharan Africa
[6,20-24]. These differences may be explained by differ-
ences in study population and risk behavior. In the ret-
rospective studies the decision to perform a diagnostic
test was based on the physicians’ expectations about dis-
ease endemicity: if schistosomiasis is not expected in a
traveler from India, one doesn’tt e s tf o ri t .A l t h o u g ht h e
seroconversion might be false-positive, cases of S. hae-
matobium in India have been reported in the past [17],
and the helminth might still be present today. In our
Table 2 Attack rates and incidence rates of seroconversions in antibody levels schistosoma spp
Parasite Region No. of sero-
conversions
Susceptibles at
risk
Person-months of
travel
Attack rate ° Incidence
rate per
1000 person-
months °
Schistosoma
spp.
All regions 5 979 782.5 0.51% (0.19-1.1%) 6.4 (2.3-14.2)
Africa 0 290 218.7 0% NA 0 NA
Asia 4 532 444.1 0.75% (0.24-1.8%) 9.0 (2.9-21.7)
Latin
America
1 157 119.8 0.64% (0.032-3.1%) 8.3 (0.42-
41.2)
S. stercoralis All regions 3 1178 936.4 0.25% (0.065-
0.69%)
3.2 (0.81-8.7)
Africa 0 290 216.4 0% NA 0 NA
Asia 3 554 463.5 0.54% (0.14-1.5%) 6.5 (1.6-17.6)
Latin
America
0 334 256.4 0% NA 0 NA
Filaria spp. All regions 1 1166 930.1 0.086% (0.004-
0.42%)
1.1 (0.054-
5.3)
Africa 0 285 214.7 0% NA 0 NA
Asia 1 549 459.8 0.18% (0.009-
0.90%)
2.2 (0.11-
10.7)
Latin
America
0 332 255.6 0% NA 0 NA
T. canis All regions 1 1185 943.3 0.084% (0.004-
0.42%)
1.1 (0.053-
5.2)
Africa 1 293 220.9 0.34% (0.017-1.7%) 4.5 (0.23-
22.3)
Asia 0 560 466.6 0% NA 0 NA
Latin
America
0 332 255,8 0% NA 0 NA
° 95% confidence interval between brackets NA: Not applicable
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travelers’ expectations about endemicity and their own
risk behavior. Thus travelers to Africa may have been
more cautious than those to Asia. More studies on dis-
ease endemicity and risk behavior are needed.
We also found that positive serology was related to
male gender and non-touristic travelling, but not to
symptomatology, as reported elsewhere [7,9,11,19-22].
The best methodological approach for estimating inci-
dence rates of clinical and subclinical travel-related hel-
minth infections is to follow a cohort of travelers
prospectively, as we did [25]. Only 5.4% of participants
were lost to follow-up, which strengthens our findings.
Nevertheless, our study has some limitations.
First, given the low number of seroconversions, our
sample size is too small to give a precise estimate of dis-
ease incidence.
Second, there may have been selection bias. Although
our subjects are comparable to the average traveler, they
were all seeking pre-travel health advice [26]. Thus they
perhaps had a more than average health awareness, par-
ticularly after receiving oral and written travel advice,
learning about the study, and agreeing to participate.
However, the effect of pre-travel consultation tends to
wane over time, and travelers may seek consultation
because they plan to visit more risky areas [21,27]. Also,
we did not have information on risk behavior at the
destination.
Third, the 112 previously infected travelers may have
been re-infected with the same parasite during this
study. Indeed, previously infected travelers may have
more risky behavior. As serologic tests cannot discrimi-
nate a new infection from a re-infection in these trave-
lers, we may have underestimated attack and incidence
rates. However, in all persons with evidence for previous
infection, the post-travel antibody level equaled the pre-
travel antibody level.
Finally, serologic testing has additional drawbacks. A
seroconversion with a slow rise in antibody levels could
have been missed, leading to underestimation. However,
most subjects donated blood more than 21 days after
return (Table 1), enough to detect a rise in antibodies in
most cases. The tests for strongyloides and filariasis can
cross-react mutually and with echinococcus spp. and
Table 3 Characteristics, symptoms, and eosinophil counts of subjects with serological evidence for recent infection
with schistosoma spp
Serological
conversion
for
Sex Age in
years
Country of
birth
Destination Travel
duration in
days
Previous travel to a
developing country
Travel-related
symptoms
Eosinophil
count per mm
3
(proportion of
leukocytes)
Pre-
travel
Post-
travel
*
1 Schist M 29 Netherlands India 42 2 - 5× Four weeks of watery
diarrhoea
40
(1.1%)
60
(1.7%)
↑
2 Schist M 36 Iran Vietnam 22 1 x None 100
(2.2%)
160
(3.1%)
↑
3 Schist M 35 Belgium Myanmar,
Thailand,
Malaysia
29 1 x Two days of watery
diarrhoea with fever
130
(2.5%)
130
(2.7%)
=
4 Schist F 26 Netherlands Thailand 21 0× None 560
(7.9%)
330
(5.1%)
↓
5 Schist F 22 Netherlands Dominican
Republic
29 0 x Three days of watery
diarrhoea
170
(3.2%)
220
(4.2%)
↑
6 Strong F 59 Netherlands China 14 2 - 5× None 80
(1.4%)
170
(2.8%)
↑
7 Strong F 48 Surinam India 24 >10× Nine days of bloody
diarrhoea and fever
130
(1.9%)
100
(1.1%)
↓
8 Strong F 65 Netherlands India 14 6 - 10× Two days of diarrhoea 320
(4.9%)
120
(1.4%)
↓
9 Fil F 54 Netherlands India 14 2 - 5× Three 2-day episodes of
watery diarrhoea.
80
(1.5%)
110
(2.3%)
↑
10 Toxo M 53 Surinam Angola 59 >10× Two weeks myalgia,
arthritis with skin rash
110
(2.1%)
130
(2.7%)
↑
Schis: Schistosoma spp. Strong: Strongyloides stercoralis Fil: Filaria spp. Toxo: Toxocara canis M: male F: female.
*) The change in the absolute eosinophil count per mm
3, post-travel versus pre-travel: ↑ indicating an increase, ↓ a decrease, and = no change.
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attack rates are very low, false positive results can occur
just by chance. This may explain why 7 subjects tested
positive for schistosomiasis or filariasis without reporting
birth or travel in an endemic country, although under-
reporting of travel-history cannot be excluded. Blood,
stool and urine microscopy could have yielded valuable
additional information, but were not part of the study pro-
tocol for logistical reasons [2]. Nevertheless, without a true
gold standard for ruling out parasitic infections, true sensi-
tivity and specificity measurements are difficult to obtain,
as are valid prevalence and incidence rates.
Conclusions
Attack rates and incidence rates of schistosomiasis,
strongyloidiasis, filariasis, and toxocariasis during one
short-term journey to an endemic area are low; routine
serological testing of returned travelers appears to be of
no value. However, previous stay or travel lead to a
cumulative risk of infection. Infection rates are difficult
to assess, as they depend on geographic distribution of
helminths, travel behavior and pre-existing immunity of
travelers, and the characteristics of diagnostic assays.
Determining the blood eosinophil count appeared to be
of no value for routine screening for helminth infections
Table 4 Potential risk factors for previous infection with schistosoma spp
Total Antibody-positive Univariate analysis Multivariate analysis
N PR PRR (95%CI) p-value PRR (95%CI) p-value
Number of subjects 1207 112 9.3% NA
Sex
Male 521 60 11.5% 1.6 (1.1-2.3) 0.020 1.6 (1.1-2.4) 0.020
Female 686 52 7.6% 1 1
Median age in years 38 43 1.01 (0.99-1.03) 0.076
(Interquartile range) (29-51) (31-54)
Country of birth
Western country 1118 100 8.9% 1 1
Non-Western country 89 12 13.5% 1.6 (0.84-3.0) 0.16 1.1 (0.58-2.2) 0.71
Previous travel to a developing country 0.022 0.14
Never 221 12 5.4% 1 1
1 to 5 times 703 64 9.1% 1.7 (0.92-3.3) 0.086 1.7 (0.83-3.3) 0.15
6 times or more 283 36 12.7% 2.5 (1.3-5.0) 0.007 2.2 (1.01-4.7) 0.048
Previous travel destinations
Not Asia 537 41 7.6% 1
Asia 670 71 10.6% 1.4 (0.96-2.1) 0.08
Not Latin America 661 51 7.7% 1 1
Latin America 546 61 11.2% 1.5 (1.02-2.2) 0.040 1.2 (0.78-1.9) 0.41
Not Africa 679 56 8.2% 1
Africa 528 56 10.6% 1.3 (0.89-1.9) 0.16
Primary purpose of current travel 0.005 0.010
Tourism 1032 84 8.1% 1 1
Work or education 99 15 15.2% 2.0 (1.1-3.6) 0.021 1.9 (1.1-3.6) 0.030
Visiting friends/relatives 76 13 17.1% 2.1 (1.2-4.4) 0.009 2.2 (1.2-4.3) 0.016
N: number of cases
PR: prevalence rate
PRR: prevalence rate ratio
CI: confidence intervals
NA: not applicable
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To improve preventive education and post travel follow-
up strategies, more prospective studies on risk and risk
behavior are needed.
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